hotspot -WSS

hotspot

author：explore 2025-10-06 07:54:34 - browse：3

Chris O'Meara/AP

Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers.

Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations. Those overpayments, the lawsuit alleges, ultimately come out of workers’ paychecks in the form of high health insurance premiums, higher out-of-pocket drug costs, and stunted wage growth.

In one example, J&J allegedly paid its PBM more than $10,000 for a single 90-day prescription of teriflunomide, a generic medicine for multiple sclerosis, when that same 90-day prescription could be purchased for as little as $30 elsewhere without insurance, according to the lawsuit.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Roche acquires Telavant from Roivant, adding experimental IBD treatment

WSS

Reports of telehealth's death have been greatly exaggerated

Study finds gene variants tied to breast cancer risk in Black women

Addressing health care workers' trauma can help fight burnout

How AI can help patients find reliable information about doctors

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

For longer

leisure time

hotspot

hotspot

Drug repurposing or repositioning? The language matters

Study on Amgen’s bispecific immunotherapy produces positive data

Jerome Adams on the need for new antivirals for Covid

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Alkermes shareholders re

Roivant's CEO is a star, but biotech's black hole persists

The high cost of giving birth even with insurance

Scrutiny of post

23andMe had bad news about my health. I wish a person had delivered it

Questions and answers about ramping up H5N1 bird flu vaccine

hotspot

Smaller biotechs seek to piggyback on weight loss drug boom

FDA poised to publish guidelines for clinical trial diversity

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

STAT Summit: How researchers deal with rejection

Cue Health, Covid

Roivant's CEO is a star, but biotech's black hole persists

focus

Wikipedia

hotspot

entertainment